Shield Therapeutics Announces Acceptance of ST10 Abstract for Presentation at ECCO Congress 2014 - WICU12 HD WSEE Erie, PA News, Sports, Weather and Events

Shield Therapeutics Announces Acceptance of ST10 Abstract for Presentation at ECCO Congress 2014

  • Chris Lifestyle Category TESTMore>>

  • COPY-Chris Test 2

    Chris Test 2

    Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1More >>
  • Chris Test 1

    Chris Test 1

    Monday, February 6 2012 4:05 PM EST2012-02-06 21:05:06 GMT
    Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Shield Therapeutics

LONDON, February 4, 2014 /PRNewswire/ --

Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 - 22 in Copenhagen, Denmark.

As recently announced, ST10, a novel orally-dosed form of ferric iron, successfully met both the primary and secondary endpoints of the AEGIS pivotal Phase III programme. With a mean increase of 2.3g/dL in ST10-treated subjects, the results of the study strongly demonstrated ST10's potential to be the only effective oral treatment for ferrous intolerant IDA patients, in addition to being an effective alternative to intravenous iron treatment.

The abstract about ST10, entitled "Correcting iron deficiency anaemia in IBD: A pivotal phase 3 study of a novel oral ferric iron", will be presented during the Digital Oral Poster Session 9 - Therapy today - in Room 9, Hall B on the Ground level of the Bella Centre at 13.07 on Friday 21st February 2014.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield has successfully completed a pivotal Phase 3 programme of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

For more information about Shield Therapeutics, please contact:

Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Lindsey Neville
Tel +44(0)20-7920-2333
Email: shieldtherapeutics@consilium-comms.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
3514 State St. Erie, PA 16508
Newsroom: (814)454-8812
Toll Free: 1(800)454-8812
Business offices: (814)454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
Mobile:
Mobile Site
Be sure to stay constantly updated with the power of WICU12 and WSEE at your fingertips
Free Android App
Free iPhone App
Free iPad App
Storm Tracker App
Droid
iPhone
iPad
All content © Copyright 2000 - 2014 WorldNow and WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com